PERFEX: Perfusion Augmentation Through Exercise

Sponsor
University of Zurich (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05584605
Collaborator
(none)
40
3
2
25
13.3
0.5

Study Details

Study Description

Brief Summary

Large cerebral vessel occlusion is a common phenomenon in the general population and accounts for 13-35% of ischemic strokes. Chronic stenosis in the large cerebral arteries is associated with cerebral hypoperfusion, cognitive decline and an increased risk of stroke or recurrent stroke, respectively.

Even with upgrowth of surgical or endovascular interventions, mechanical reopening of the occluded vessels is often not possible. Alternative treatment opportunities include minimal-to-moderate blood pressure elevation (typically by ceasing antihypertensives) waiting for collateral circulation to develop spontaneously. Another conservative approach to increase cerebral perfusion is aerobic exercising. Physical activity has shown to lead to cerebral blood flow increase, especially in activated brain areas of healthy human and rat models. However, it is remains unknown, how physiological adaptation to physical activity expresses in persons after stroke due to large vessel occlusion. Herein, it is hypothesized that aerobic exercise facilitates the development of an extensive and functional vascular collateral network in persons with ischemic stroke and perfusion compromise.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Aerobic treadmill training
  • Behavioral: Stretching exercise
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Changes in PERFusion and Cerebrovascular Reactivity Through Aerobic EXercise Training After Ischemic Stroke - a Proof of Concept Randomized Controlled Trial
Anticipated Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: aerobic treadmill training

Progressive graded, high-intensity aerobic treadmill training is delivered over 36 sessions at a frequency of 3x per week for 30-50 minutes of training per session over a period of 3 months. If possible, the training intensity is progressed from 40% to 80% of heart rate reserve, according to the supervising therapist.

Behavioral: Aerobic treadmill training
The intervention will be delivered based on the initial exercise testing and graded based by increasing the duration, speed and/or altitude of the treadmill training.

Active Comparator: stretching exercise

The control intervention includes stretching exercise therapy similarly heart rate controlled within limits up to 20% of heart rate reserve over 36 sessions at a frequency of 3x per week for 30 minutes.

Behavioral: Stretching exercise
Interventions, such as stretching, relaxation, passive soft-tissue technics (excl. manipulation) that do not elevate the heart rate above 20HRR

Outcome Measures

Primary Outcome Measures

  1. Brain imaging - cerebrovascular reactivity (CVR) by BOLD-fMRI [post-intervention (12 weeks)]

    Functional brain tissue perfusion and tissue at risk based on cerebrovascular reactivity by blood oxygenation-level dependent functional magnetic resonance imaging (BOLD-fMRI), measured as the percentage BOLD signal change /mmHg CO2.

Secondary Outcome Measures

  1. Brain imaging - intravoxel incoherent motion (IVIM) [post-intervention (12 weeks)]

    Functionality of brain microvasculature by measuring diffusion and perfusion components of tissue based on intravoxel incoherent motion

  2. Brain imaging - NOVA-qMRI [post-intervention (12 weeks)]

    Blood flow velocity based on non-invasive optimal vessel analysis quantitative magnetic resonance imaging

  3. Brain imaging - Lesion volume [post-intervention (12 weeks)]

    based on 3D T1 weighted imaging, 3D Fluid-Attenuated Inversion Recovery (FLAIR), Diffusion-Eighted Imaging (DWI)

  4. Brain imaging - Collateral status [post-intervention (12 weeks)]

    Collateral status based on 3D time of flight angiography (TOF)

  5. Exercise stress testing [post-intervention (12 weeks)]

    Cycle ergometer testing with spirometry

  6. Six-Minute Walk Test (6MWT) [post-intervention (12 weeks) + follow-up (+3 months)]

    Functional walking capacity in meters

  7. Ten-Meter Walk Test (10MWT) [post-intervention (12 weeks) + follow-up (+3 months)]

    Walking speed in m/s

  8. Fugl-Meyer Assessment of the Lower Extremity (FMMA-LE) [post-intervention (12 weeks) + follow-up (+3 months)]

    Stroke-specific motor impairment index to assess lower limb motor function with a total score ranging from 0 to 34 and higher scores indicating better performance.

  9. Motricity Index of the Lower Extremity (MI-LE) [post-intervention (12 weeks) + follow-up (+3 months)]

    Muscle strength assessment of three major muscle groups of the lower extremity with a total score ranging from 0 to 100 and higher scores indicating better performance.

  10. 5-Chair-Rise-Test [post-intervention (12 weeks) + follow-up (+3 months)]

    Functional muscle strength, measured in seconds to complete the task.

  11. International Physical Activity Questionnaire (IPAQ) [post-intervention (12 weeks) + follow-up (+3 months)]

    self-reported physical activity

  12. Montreal Cognitive Assessment (MoCA) [post-intervention (12 weeks) + follow-up (+3 months)]

    Screening assessment of cognitive functions with a maximum score of 30 points.

  13. Word list learning [post-intervention (12 weeks) + follow-up (+3 months)]

    Assessment of memory function

  14. Digit Span Test / Corsi block [post-intervention (12 weeks) + follow-up (+3 months)]

    Assessment verbal and nonverbal working memory

  15. Stroop test [post-intervention (12 weeks) + follow-up (+3 months)]

    Assessment of executive function and inhibition

  16. European Quality of Life 5 Dimensions 5 Level (5Q-5D-5L) [post-intervention (12 weeks) + follow-up (+3 months)]

    Quality of life questionnaire that assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) on a 5-level scale ranging from 1 - no, 2 - slight, 3 - moderate, 4 - severe to 5 - extreme problems or unstable to.

Other Outcome Measures

  1. Concomitant medications [post-intervention (12 weeks) + follow-up (+3 months)]

    covariate

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male and Female patients of 18 years of age or above

  • Subjects after ischemic cerebral stroke (≥ 3 months) due to large vessel occlusion

  • Subjects do not qualify for flow augmentation through ECIC bypass or endovascular treatment

  • Persistent deficit in BOLD-CVR

  • Functional Ambulatory Categories >2

  • Discharged from hospitalization / inpatient rehabilitation

  • Living independent before stroke (mRS ≤3)

  • Written Informed Consent

Exclusion Criteria:
  • Severe cardiac disease, such as instable angina pectoris, pericarditis, heart failure (New York Health Association > II°), or hemodynamically significant valvular dysfunction

  • Complete arterial stenosis

  • Peripheral artery disease with mild to moderate claudication at < 200m or 200-1000m of walking

  • Contra-indication, such as a history of a seizure, prior electroconvulsive therapy, deep brain stimulators or other metal in the head, skull defect, pacemaker, neuroleptic medication

  • Inability to follow the procedures of the study, e.g., due to language problems (unable to follow to stage commands), psychological disorders (major depression), and / or a neurodegenerative disease (dementia)

  • Known or suspected non-compliance, documented drug, or alcohol abuse

  • Pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ambulante Reha Triemli Zürich Zürich Switzerland
2 Klinik Lengg AG Zürich Switzerland
3 University Hospital Zurich Zürich Switzerland

Sponsors and Collaborators

  • University of Zurich

Investigators

  • Principal Investigator: Christoph Globas, MD, University Hospital and University of Zurich

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Zurich
ClinicalTrials.gov Identifier:
NCT05584605
Other Study ID Numbers:
  • 2022-00438
First Posted:
Oct 18, 2022
Last Update Posted:
Oct 18, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Zurich
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 18, 2022